2541 results about "Monoclonal" patented technology

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

The invention belongs to the technical field of biology, and particularly relates to a group of paired monoclonal antibodies for resisting H9N2 subtype avian influenza viruses and a surface enhanced Raman spectroscopy rapid detection test strip established based on the antibodies. The paired monoclonal antibody comprises a labeled antibody 1E9 and a capture antibody 3C10 which are prepared by taking hemagglutinin protein of the H9N2 subtype avian influenza virus as antigens and can be specifically combined with the H9N2 subtype avian influenza virus. According to the invention, an SERS (Surface Enhanced Raman Scattering) probe Au-coated Pt-4ATP is used as a marker and is coupled with a labeled antibody 1E9 to prepare a labeled probe, and the labeled probe is paired with a capture antibody 3C10 to establish an SERS immunochromatography test strip. The test strip has a colorimetric and Raman dual interpretation mode, can be used for qualitative and quantitative detection, has the advantages of strong specificity, high sensitivity, good repeatability and stability and the like, is simple and rapid in clinical detection operation, and provides reliable technical support for on-site rapid screening of subtype viruses.

The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.

The invention relates to the technical field of molecular biology, in particular to an avian adenovirus serum type 4 colloidal gold test strip based on a monoclonal antibody and application of the test strip. According to the invention, two monoclonal antibodies (6B3 and 8G11) aiming at FAdV4 penton protein are successfully prepared through a hybridoma technology, and both the monoclonal antibodies show high titer and strong serotype specificity. Specific analysis proves that the two monoclonal antibodies can recognize 12 FAdV4 isolates from different sources, and do not have cross reaction with other FAdV serotypes or common poultry pathogens. According to the invention, through systematic optimization of key parameters, the detection sensitivity of the test strip is 7.81 * 10 < 4 > TCID50 / 0.1 mL, and the detection time is only 15 minutes. Clinical sample verification shows that compared with an ELISA method, the total coincidence rate is 98.6%.

The invention belongs to the technical field of biological medicine, and particularly relates to a kit for breast cancer diagnosis and application thereof. The kit comprises an elisa plate coated with a captured antibody and an HRP labeled antibody working solution, the capture antibody is a monoclonal antibody T2X-1 of an anti-PSTPIP1 protein; the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an anti-PSTPIP1 protein, and the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an The heavy chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.1, and the light chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.2; the heavy chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.4. The kit for breast cancer diagnosis provided by the invention can be used as an auxiliary diagnosis means for breast cancer with high expression of PSTPIP1 protein, and has high diagnostic value.

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

The invention relates to the field of biological detection, in particular to a monoclonal antibody combination for detecting human IL-6 protein and application. The combination comprises monoclonal antibodies 3A10 and 2G1, and amino acid sequences of complementary determining regions of variable regions of light and heavy chains of the monoclonal antibodies 3A10 and 2G1 are respectively shown as SEQ ID NO.1-12. The invention defines a complete variable region sequence and a coding nucleotide sequence of the antibody. The combination specifically recognizes human IL-6 recombinant and natural proteins, and has no cross reaction with IL-11. A double-antibody sandwich ELISA kit constructed based on the combination takes 3A10 as a coating antibody and 2G1 as a labeled antibody, and has high sensitivity and high specificity. The problems that an existing reagent is insufficient in specificity and low in sensitivity are solved, a reliable core raw material is provided for IL-6 standardized detection, and the method is suitable for preparation of a kit, a test strip and an antibody chip.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody pair for detecting feline immunodeficiency virus p24 protein and application thereof. The monoclonal antibody pair is monoclonal antibody 1D8 and monoclonal antibody 1H10, which can specifically recognize feline immunodeficiency virus p24 protein, and the heavy chain and light chain variable region complementarity determining region sequences of 1D8 and 1H10 are clear, and are respectively shown as SEQ ID NO. 1-12. The antibody pair can effectively avoid cross reaction, and significantly improve the accuracy and sensitivity of detection; the colloidal gold detection test strip constructed based on the antibody pair is simple and fast in operation, is suitable for early antigen detection of FIV infection, solves the problem that existing antibody detection cannot distinguish natural infection and vaccine immunization, and provides a reliable technical means for on-site screening and disease prevention and control of FIV.

The invention belongs to the technical field of colloidal gold immunochromatography, and relates to a cetirizine monoclonal antibody, a nucleic acid molecule, a carrier, a detection kit and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, the sequence of the VH-CDR2 is as shown in SEQ ID NO.2, and the sequence of the VH-CDR3 is as shown in SEQ ID NO.3. The invention further discloses a preparation method of the cetirizine monoclonal antibody. The monoclonal antibody provided by the invention has high sensitivity to cetirizine, the lowest detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting canine parainfluenza virus NP protein and application thereof. The combination is composed of monoclonal antibodies 5H10 and 1H7, 5H10 is used as a coating antibody, and 1H7 is used for colloidal gold labeling, so that efficient and specific sandwich detection of CPIV / NP antigen can be realized. The variable region CDR sequences of the heavy chains and light chains of the two antibodies are clear (SEQ ID NO. 1-12). The application also provides a rapid detection test strip based on the antibody combination, which can be used for on-site screening, early diagnosis and epidemiological monitoring of canine parainfluenza virus, solves the problem that existing detection technologies lack high-specificity recognition tools, and has a good application prospect.

The invention provides a group of monoclonal antibody pairs targeting adenovirus DBP protein, the monoclonal antibody pairs comprise a capture antibody and a detection antibody, each of the two antibodies comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, the light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, and the capture antibody and the detection antibody are used for capturing and detecting the adenovirus DBP protein. Wherein the capture antibody is a monoclonal antibody 19E3; and the detection antibody is selected from a monoclonal antibody 96 to 10D8, a monoclonal antibody 95 to 2B7, a monoclonal antibody 96 to 2C10, a monoclonal antibody 96 to 8E10, a monoclonal antibody 96 to 13D5 or a monoclonal antibody 96 to 2B10. The monoclonal antibody pair disclosed by the invention can be used for efficiently detecting various types of HAdV DBP.

The invention relates to the technical fields of gene engineering, antibody engineering and immunodiagnosis. The invention provides a recombinant humanized anti-Cpn IgM monoclonal antibody. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are respectively shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5; the heavy chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are shown as SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8 respectively. The invention also provides a method for preparing the monoclonal antibody. The recombinant humanized anti-Cpn IgM monoclonal antibody provided by the invention is expressed in mammalian cells by utilizing a gene recombination technology, has the characteristics of high purity, small batch difference and the like, and can be applied to a Cpn IgM antibody detection kit as a quality control product; as a quality control product, the recombinant humanized anti-Cpn IgM monoclonal antibody has the advantages of high sensitivity, high safety, inter-batch stability and the like.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 1D3 for detecting porcine epidemic diarrhea virus (PEDV) and its applications. Its heavy chain variable region CDR sequences are SEQ ID NO. 1-3, and its light chain variable region CDR sequences are SEQ ID NO. 4-6. This antibody specifically recognizes the PEDV / S1 protein, and its binding can be competitively blocked by PEDV-specific neutralizing antibodies in serum, making it suitable for establishing a blocking ELISA method. Detection tools based on this antibody exhibit high specificity and sensitivity, with blocking rates exceeding 50% against PEDV-positive serum. This invention can be used to prepare detection kits or evaluate vaccine immunization efficacy, providing an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention relates to a hybridoma cell strain capable of secreting a mefos monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, the hybridoma cell strain capable of secreting the fenofos monoclonal antibody is obtained through screening, the fenofos monoclonal antibody has high specificity and high sensitivity to the fenofos, IC50 to the fenofos is 0.231 ng / mL, and the fenofos monoclonal antibody has no cross reaction to structural analogues of the fenofos, such as triazophos, diazinon, phorate, acetyl phorate, methamidophos and the like; therefore, low-concentration isoprophos can be accurately detected.

The present invention provides a rabies virus G protein antigen epitope targeting completely human monoclonal antibody and applications thereof, the completely human monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP, and the light chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QGISND, ATS and LQDYEFPLT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of bovine coronavirus S2 protein, an epitope of the monoclonal antibody and application of the epitope. The invention provides a hybridoma cell strain (preservation number: CCTCC (China Center For Type Culture Collection) NO: C202510). The cell strain can secrete a monoclonal antibody which is targeted and combined with bovine coronavirus S2 protein; the amino acid sequence of the epitope identified by the monoclonal antibody is shown as SEQ ID NO: 1. Experiments prove that the monoclonal antibody has neutralizing activity, and the targeting epitope of the monoclonal antibody is a key neutralizing epitope. The invention provides a new strategy and tool for antibody drug and vaccine research and development as well as diagnosis and detection of the bovine coronavirus.

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

The invention discloses a test strip for detecting etoxazole and application of the test strip. The test strip comprises a sample absorption pad (1), a conjugate release pad (2), a reaction film (3), a water absorption pad (4) and a bottom plate (7), the reaction film is provided with a detection line (5) coated with an etoxazole hapten-carrier protein conjugate and a quality control line (6) coated with a goat anti-mouse antibody, and the conjugate release pad (2) is sprayed with an etoxazole monoclonal antibody-colloidal gold marker. The invention also provides a method for detecting residual etoxazole in vegetables and fruits by using the etoxazole test strip. The test strip provided by the invention has the characteristics of simplicity in operation, high sensitivity, high detection speed, low cost and the like, and is suitable for screening and on-site monitoring of a large number of samples.

The invention discloses a T-2 toxin monoclonal antibody and application thereof, and belongs to the technical field of biology. The monoclonal antibody contains a heavy chain variable region and a light chain variable region, the heavy chain variable region and the light chain variable region are both composed of complementary determining regions and frame regions, and the complementary determining regions are both composed of CDR1, CDR2 and CDR3. The monoclonal antibody can be used for preparing a T-2 toxin detection product. The T-2 toxin colloidal gold test strip provided by the invention has the characteristics of high sensitivity, good specificity and strong stability.

The application provides an AFP detection kit and application thereof, relates to the technical field of tumor marker detection, and the kit is a double-antibody sandwich ELISA kit. The kit contains two AFP monoclonal antibodies, AFPH8 and AFPE2. The amino acid sequences of the CDR of the heavy chain of AFPH8 are shown in SEQ ID NO. 4-6, the amino acid sequences of the CDR of the light chain of AFPH8 are shown in SEQ ID NO. 7-9, the amino acid sequences of the CDR of the heavy chain of AFPE2 are shown in SEQ ID NO. 12-14, and the amino acid sequences of the CDR of the light chain of AFPE2 are shown in SEQ ID NO. 15-17. Experiments show that the kit has high sensitivity and can detect slightly elevated AFP in initial serum.

The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1,3-galactose, a known red meat allergen, and methods for use thereof.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination for detecting porcine epidemic diarrhea virus (PEDV) S protein and its application. The combination comprises monoclonal antibodies 4E11 and 1F3. The heavy chain CDR1-3 (SEQ ID NO. 1-3) and light chain CDR1-3 (SEQ ID NO. 4-6) of 4E11, and the heavy chain CDR1-3 (SEQ ID NO. 7-9) and light chain CDR1-3 (SEQ ID NO. 10-12) of 1F3, together impart high specificity and affinity. Detection methods such as double-antibody sandwich ELISA constructed based on this combination, using 4E11 as the coating antibody and 1F3 as the labeling antibody, have advantages such as high sensitivity, strong specificity, and broad spectrum, and can be used for in vitro detection of PEDV S protein, biological sample analysis, and quality control of biological products.

The application belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody specifically recognizing type II grass carp reovirus VP4 protein, a eukaryotic expression method and application. The S6 gene in GCRV-II encodes VP4 protein, the application transfects the target gene S6 into HEK293 cells for expression and purification, cooperates with Freund's adjuvant to immunize New Zealand white rabbits, and uses ELISA, single B cell screening and eukaryotic expression technology to obtain a rabbit-derived recombinant monoclonal antibody specifically recognizing GCRV-II VP4 protein. The antibody has strong specificity, provides support for further establishment of specific type II grass carp reovirus diagnosis technology, and has great application value for development of GCRV-II related scientific research.

The present invention relates to an antibody or an antigen-binding fragment thereof binding to CLDN18.2, an antibody-drug conjugate comprising same, and a use of the antibody and the antibody-drug conjugate. An anti-CLDN18.2 monoclonal antibody according to the present invention comprises a fully human antibody sequence, thereby having low in vivo immunogenicity, and exhibits excellent antigen affinity and binding ability specific to a low expression to a high expression level of the CLDN18.2 protein. Thus, the antibody is expected to exhibit high specificity and safety as an antibody-based therapeutic agent such as in the form of a monoclonal antibody and / or an antigen-binding fragment (scFv), an antibody-drug conjugate (ADC), an immune cell engager, a chimeric antigen receptor (CAR), a multispecific antibody, and the like. In addition, the antibody according to the present invention may undergo cellular internalization, enables an anti-CLDN18.2 antibody-drug conjugate comprising said antibodies to be conveniently prepared, and has excellent yield and quality and thus is expected to be highly likely to be developed as a drug. A drug conjugate comprising the anti-CLDN18.2 antibody according to the present invention has excellent in vivo anticancer efficacy and has an expanded therapeutic index (TI) and thus is expected to be usefully employable for the treatment and / or prevention of cancer diseases expressing CLDN18.2 and related diseases.

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.

The invention relates to a medetomidine hapten, a monoclonal antibody, a hybridoma cell strain and application thereof, and belongs to the technical field of immunodetection. A medetomidine complete antigen is obtained by synthesizing a medetomidine hapten, a mouse is used as an immune animal to prepare a hybridoma cell strain secreting a medetomidine monoclonal antibody, the hybridoma cell strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46518. The medetomidine monoclonal antibody secreted by the hybridoma cell strain has better detection sensitivity and detection specificity to medetomidine, the IC50 value is 10.42 ng / mL, and the cross reaction rate to various medetomidine analogues is lt; the method can be applied to preparation of medetomidine detection products, and provides a reliable tool for immunodetection of medetomidine.

The invention relates to a monoclonal antibody DIDA55 aiming at hog cholera virus, and a preparation method and application thereof, belonging to the field of medical preparations. The monoclonal antibody DIDA55 or an antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, amino acid sequences of LCDR1, LCDR2 and LCDR3 in a light chain variable region of the antibody are shown as 24th to 34th, 50th to 56th and 89th to 97th in SEQ ID No: 4; amino acid sequences of HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of the antibody are shown as the 31st to 35th, the 50th to 65th and the 95th to 102th of SEQ ID No: 5. The monoclonal antibody provided by the invention can be used in the fields of swine fever E2 protein labeled subunit vaccine immunity, serological diagnosis of wild strains, swine fever vaccine immune effect evaluation, related experiments and the like, and provides antibody resources for prevention, control and purification of CSF.

The invention belongs to the technical field of immunochemistry, and particularly relates to an anti-PR recombinant rabbit monoclonal antibody and application thereof.The anti-PR recombinant rabbit monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO: 4; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 5. The invention also relates to a nucleotide sequence for coding the anti-PR recombinant rabbit monoclonal antibody, a recombinant plasmid or an expression vector, a preparation method, application of the anti-PR recombinant rabbit monoclonal antibody in a PR protein detection method or device, and the like. The PR recombinant rabbit monoclonal antibody disclosed by the invention has the characteristics of good specificity, strong positive signal and the like, so that scoring is easier in IHC staining, and cancer detection and distinguishing are more accurate.

A system and method for determining charge variants in monoclonal antibodies using raman spectroscopy is disclosed.